Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584761 | 1.00 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1MAPTKMT2AMEN1 | |
| SCHEMBL2384186 | 1.00 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1MAPTKMT2AMEN1 | |
| SCHEMBL1968848 | 0.90 | NAAA (0.48) | ALDH1A1MAPTCYP2C9CYP2C19CYP1A2 | |
| SCHEMBL2221132 | 0.90 | NAAA (0.48) | ALDH1A1MAPTCYP2C9CYP2C19CYP1A2 | |
| SCHEMBL14408397 | 0.87 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1MAPTKMT2AMEN1 | |
| SCHEMBL16673135 | 0.87 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1MAPTKMT2AMEN1 | |
| SCHEMBL10472516 | 0.84 | L3MBTL1 (0.64) | ALDH1A1L3MBTL1MAPTKMT2AMEN1 | |
| SCHEMBL3813646 | 0.84 | L3MBTL1 (0.64) | ALDH1A1L3MBTL1MAPTKMT2AMEN1 | |
| SCHEMBL28008702 | 0.84 | TSHR (0.54) | ALDH1A1L3MBTL1KMT2AMEN1SLC1A3 | |
| SCHEMBL25980247 | 0.84 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758385-B1 | PROCESS FOR THE PREPARATION OF TRIAZOLE ANTIFUNGAL DRUG, ITS INTERMEDIATES AND POLYMORPHS THEREOF | MSN LAB LTD (IN) | 2018-03-28 | — | — | EP | claimed |
| US-20140343285-A1 | Process for the Preparation of Triazole Antifungal Drug, Its Intermediates and Polymorphs Thereof | MSN LABORATORIES LIMITED (IN) | 2014-11-20 | — | — | US | claimed |
| EP-2758385-A2 | PROCESS FOR THE PREPARATION OF TRIAZOLE ANTIFUNGAL DRUG, ITS INTERMEDIATES AND POLYMORPHS THEREOF | MSN Laboratories Limited (IN) | 2014-07-30 | — | — | EP | claimed |
| WO-2013042138-A2 | PROCESS FOR THE PREPARATION OF TRIAZOLE ANTIFUNGAL DRUG, ITS INTERMEDIATES AND POLYMORPHS THEREOF | MSN LABORATORIES LIMITED (IN) | 2013-03-28 | — | — | WO | claimed |
| EP-4630417-A1 | NOVEL COMPOUNDS AS MODULATORS OF NLRP3 INHIBITION | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024121086-A1 | NOVEL COMPOUNDS AS MODULATORS OF NLRP3 INHIBITION | F. HOFFMANN-LA ROCHE AG (CH) | 2024-06-13 | — | — | WO | disclosed |
| EP-3632907-B1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-3632907-B1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2024-02-28 | — | — | EP | disclosed |
| CN-117425661-A | Macrocyclic LRRK2 kinase inhibitors | 法国施维雅药厂 | 2024-01-19 | — | — | CN | disclosed |
| CN-117177974-A | Imidazole-containing condensed ring derivative, preparation method and medical application thereof | 长春金赛药业有限责任公司 | 2023-12-05 | — | — | CN | disclosed |
| CN-116693447-A | Ketone amide derivative and pharmaceutical application thereof | 成都威斯克生物医药有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | disclosed |
| CN-100503609-C | 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2, 4-triazolo [1,5-c]-pyrimidine adenosine A2areceptor antagonist | SCHERING CORP (US) | 2009-06-24 | — | — | CN | disclosed |
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| CN-1777609-A | 2-alkynyl-and 2-alkenyl-pyrazolo- [4, 3-e]-1, 2, 4-triazolo [1, 5-c]-pyrimidine adenosine A2aReceptor antagonists | SCHERING CORP (US) | 2006-05-24 | — | — | CN | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | ALDH1A1 3735/4885L3MBTL1 1749/4885MAPT 4844/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | ALDH1A1 591/4885L3MBTL1 3697/4885MAPT 2814/4885 |
| US-20140343285-A1 | Process for the Preparation of Triazole Antifungal Drug, Its Intermediates and Polymorphs Thereof | CYP3A4, CYP51A1, CYP1B1 | ALDH1A1 372/4885L3MBTL1 4374/4885MAPT 1385/4885 |
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | PPARA, PPARD, PPARG | ALDH1A1 461/4885L3MBTL1 4855/4885MAPT 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.